Medivir AB (MVRBF) Release: Results From the COSMOS Study With Simeprevir and Sofosbuvir in Cirrhotic and Non-Cirrhotic HCV genotype 1 Patients Presented at American Association for Study of Liver Diseases
11/5/2013 9:42:19 AM
Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced data from the
interferon-free COSMOS study demonstrating safety and efficacy of the
investigational protease inhibitor simeprevir (TMC435) in combination with the
investigational nucleotide inhibitor sofosbuvir (GS-7977), with and without
ribavirin, in genotype 1 chronic hepatitis C adult patients with compensated
liver disease was presented at the Annual Meeting of the American Association
for the Study of Liver Diseases (AASLD) in Washington, D.C. during the late
-breaking oral session on Monday, November 4.
Help employers find you! Check out all the jobs and post your resume.
comments powered by